Corporate Information, English, IR, News, Other Corporate Information

Acarix confirms timing of Q1 webcast presentation

  • Posted by author-avatar
12 May

The pre-recorded webcast presentation featuring CEO Aamir Mahmood, along with the PDF version of the presentation, will be available on our website today at 13:00 CET.

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 40,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

For more information, contact
Macie May, phone +1 405 517 5161, email mmay@saxum.com

Attachments
Acarix confirms timing of Q1 webcast presentation

Acarix confirms timing of Q1 webcast presentation
Newer Announcement from the annual general meeting in Acarix AB
Back to list
Older Acarix Publishes Interim Report, January – March 2025